Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 known ✓ | P51681 | 6/20 | 0.48 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.39 |
| ▸ | OPRD1 known ✓ | P41143 | 1/20 | 0.39 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.39 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 3/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1450171 | 0.94 | CCR5 (0.49) | CCR5MCHR1ALDH1A1LMNAPTBP1 | |
| Hydrochloric Acid SCHEMBL1449263 | 0.93 | CCR5 (0.51) | CCR5MCHR1ALDH1A1LMNAPTBP1 | |
| Hydrochloric Acid SCHEMBL1449664 | 0.93 | CCR5 (0.49) | CCR5MCHR1ALDH1A1LMNAPTBP1 | |
| Hydrochloric Acid SCHEMBL1448812 | 0.92 | CCR5 (0.52) | CCR5MCHR1ALDH1A1LMNAPTBP1 | |
| Hydrochloric Acid SCHEMBL1449291 | 0.92 | CCR5 (0.52) | CCR5MCHR1ALDH1A1LMNAPTBP1 | |
| Hydrochloric Acid SCHEMBL1448795 | 0.91 | CCR5 (0.47) | CCR5MCHR1ALDH1A1LMNAPTBP1 | |
| Hydrochloric Acid SCHEMBL1449301 | 0.91 | CCR5 (0.46) | CCR5MCHR1ALDH1A1LMNAPTBP1 | |
| Hydrochloric Acid SCHEMBL1449730 | 0.91 | CCR5 (0.48) | CCR5MCHR1ALDH1A1LMNAPTBP1 | |
| Hydrochloric Acid SCHEMBL1449273 | 0.90 | CCR5 (0.47) | CCR5MCHR1ALDH1A1LMNAPTBP1 | |
| Hydrochloric Acid SCHEMBL1448917 | 0.90 | CCR5 (0.52) | CCR5MCHR1LTA4HPRKAA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150087720-A1 | Dosage Regimen of an S1P Receptor Agonist | NOVARTIS AG (CH) | 2015-03-26 | — | — | US | claimed |
| US-20090275553-A1 | DOSAGE REGIMEN OF AN S1P RECEPTOR AGONIST | KOVARIK JOHN M | 2009-11-05 | — | — | US | claimed |
| US-20080221200-A1 | Combination of Organic Compounds | ALLISON MALCOLM | 2008-09-11 | — | — | US | claimed |
| EP-1940388-A2 | DPP IV INHIBTOR FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES AND GRAFT REJECTION | Novartis AG (CH) | 2008-07-09 | — | — | EP | claimed |
| WO-2007041368-A2 | DPP IV INHIBITOR FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES AND GRAFT REJECTION | NOVARTIS AG (CH) | 2007-04-12 | — | — | WO | claimed |
| US-20220031609-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2022-02-03 | — | — | US | disclosed |
| US-20200237690-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2020-07-30 | — | — | US | disclosed |
| US-20190175527-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2019-06-13 | — | — | US | disclosed |
| US-20170290787-A1 | Organic Compounds | NOVARTIS AG (CH) | 2017-10-12 | — | — | US | disclosed |
| US-20160101179-A1 | COMPOUND FORMULATIONS OF 2-AMINO-1, 3-PROPANEDIOL COMPOUNDS | BURANACHOKPAISAN THITIWAN (US) | 2016-04-14 | — | — | US | disclosed |
| EP-2316431-B1 | Solid oral composition comprising a S1P receptor agonist and a sugar alcohol | NOVARTIS AG (CH) | 2015-09-30 | — | — | EP | disclosed |
| US-20150087720-A1 | Dosage Regimen of an S1P Receptor Agonist | NOVARTIS AG (CH) | 2015-03-26 | — | — | US | disclosed |
| US-20050215531-A1 | Use of edg receptor binding agents in cancer | BAUMRUKER THOMAS | 2005-09-29 | — | — | US | disclosed |
| EP-1575576-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2005-09-21 | — | — | EP | disclosed |
| WO-2005058295-A2 | USE OF SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR AGONISTS FOR THE TREATMENT OF BRAIN DEGENERATIVE DISEASES | NOVARTIS AG (CH) | 2005-06-30 | — | — | WO | disclosed |
| EP-1505959-A1 | USE OF EDG RECEPTOR BINDING AGENTS IN CANCER | Novartis AG (CH) | 2005-02-16 | — | — | EP | disclosed |
| WO-2004089341-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2004-10-21 | — | — | WO | disclosed |
| WO-2004028521-A2 | SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS IN THE TREATMENT OF DEMYELINATING DISORDERS | NOVARTIS AG (CH) | 2004-04-08 | — | — | WO | disclosed |
| WO-2004010987-A2 | USE OF S1P RECEPTOR AGONISTS IN HEART DISEASES | NOVARTIS AG (CH) | 2004-02-05 | — | — | WO | disclosed |
| WO-2003097028-A1 | USE OF EDG RECEPTOR BINDING AGENTS IN CANCER | NOVARTIS AG (CH) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190175527-A1 | ORGANIC COMPOUNDS | GPR119, OPRM1, FFAR1 | CCR5 622/4885OPRM1 2/4885OPRD1 13/4885 |
| US-20050215531-A1 | Use of edg receptor binding agents in cancer | S1PR3, S1PR1, S1PR4 | CCR5 182/4885OPRM1 1488/4885OPRD1 1814/4885 |
| US-20080221200-A1 | Combination of Organic Compounds | DPP4, DPP3, DPP7 | CCR5 704/4885OPRM1 2741/4885OPRD1 1690/4885 |
| US-20220031609-A1 | ORGANIC COMPOUNDS | GPR119, OPRM1, FFAR1 | CCR5 622/4885OPRM1 2/4885OPRD1 13/4885 |
| US-20090275553-A1 | DOSAGE REGIMEN OF AN S1P RECEPTOR AGONIST | S1PR1, S1PR2, S1PR4 | CCR5 142/4885OPRM1 374/4885OPRD1 209/4885 |
| US-20150087720-A1 | Dosage Regimen of an S1P Receptor Agonist | S1PR1, S1PR2, S1PR4 | CCR5 142/4885OPRM1 374/4885OPRD1 209/4885 |
| US-20170290787-A1 | Organic Compounds | GPR119, OPRM1, FFAR1 | CCR5 622/4885OPRM1 2/4885OPRD1 13/4885 |
| US-20160101179-A1 | COMPOUND FORMULATIONS OF 2-AMINO-1, 3-PROPANEDIOL COMPOUNDS | ACMSD, AASDHPPT, DDC | CCR5 1622/4885OPRM1 757/4885OPRD1 136/4885 |
| US-20200237690-A1 | ORGANIC COMPOUNDS | GPR119, OPRM1, FFAR1 | CCR5 622/4885OPRM1 2/4885OPRD1 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.